Afya (NASDAQ:AFYA) Stock, Quote.Headers.trade-ideas

Afya

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medicine, other health sciences, and other undergraduate programs, Continuing Education provides specialization programs and graduate courses in medicine; and Digital Services provides content and technology for medical education, clinical decisions software, practice management tools (that encompass electronic medical records, telemedicine, and digital prescription, and provides access, demand and efficiency for the healthcare players.

zscaler shutter2

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AFYA

CLSK

FRME

GRDN

INDI

TMDX

Zscaler, TransMedics Group And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Earnings

Small Cap

Analyst Ratings

Adtalem Global Education Inc. Common Stock

ATGE

Afya Limited (NASDAQ: AFYA) completed the acquisition of the total share capital of Unidom Participacoes S.A. (Unidompedro and Faculdade Dom Luiz) through its wholly-owned subsidiary Afya Participacoes S.A.

AFYA Welcomes 300 Operational Medical School Seats in Salvador

Price Target

CRWD

CTVA

GEHC

ODFL

SCCO

SNPS

TEVA

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

CrowdStrike To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday

Afya Ltd

- Presentation&nbsp;
&nbsp;
<figure class="image"><img src="https://www.sec.gov/Archives/edgar/data/1803901/000095017025005641/talk-ex99_1s19.jpg" alt="Slide 19" /></figure>

Guidance

TALK

Talkspace Sees 2024 Revenue Guidance Of ~$185M-$195M, Up 23%-30% YoY; 3-Year Revenue CAGR Outlook Of 20%-25%

VCIG

VCI Global Announces Exclusive Distributorship Of Secure Encryption Storage Limited For Data Security Solutions In Malaysia

WIIM

CVGW

Calavo Growers shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results.

PRTH

Priority Technology shares are trading lower after the company announced a share offering of 9,157,600 shares.

CEO Marc Rowan to Enter Into 5-Year Employment Agreement Extension
Jim Zelter Named President of Apollo Global Management
John Zito Named Co-President of Apollo Asset Management Alongside Scott Kleinman
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) today announced that Jim Zelter has been named President of Apollo Global Management, Inc. (AGM), the holding company for its asset management and retirement services businesses. The newly created role reflects Apollo's continued operational expansion and its significant growth plans across both the Apollo Asset Management, Inc. (AAM) and Athene Holding Ltd. subsidiaries. As President, Zelter will work closely with AGM CEO Marc Rowan to drive Apollo's recently announced five-year plan and lead a number of key strategic initiatives across its asset management and retirement services businesses.

Management

Apollo Announces Jim Zelter As President Of Apollo Global Management; John Zito Named Co-President Of Apollo Asset Management With Scott Kleinman; CEO Marc Rowan Signs 5-Year Agreement Extension

TOMZ

TOMI Environmental Solutions Regains Compliance With Nasdaq Requirements

GNLN

Greenlane Regains Full Compliance With Nasdaq Continued Listing Rules
ACCESSWIRE

KROS

Keros Therapeutics shares are trading lower after the company announced an update on its Phase 2 TROPOS trial and halted all dosing based on the ongoing safety review.

JP Morgan analyst Tami Zakaria maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Neutral and raises the price target from $450 to $470.

JP Morgan Maintains Neutral on Deere, Raises Price Target to $470

QUBT

Quantum Computing Collaborates With Sanders Tri-Institutional Therapeutics Discovery Institute To Support Research Using Dirac-3 Systems

BECN

QXO Proposes To Acquire Beacon Roofing Supply For $124.25/Share In Cash, Implying Total Transaction Valued Of ~$11B

Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company's FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels available.
xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients. xT CDx leverages a normal-matched approach, which is a method of parallel DNA sequencing of a solid tumor and normal patient sample that can lead to more accurate identification of cancer-driving somatic variants. All orders for tumor + normal match tests – traditionally run on the company's signature xT assay – will now be run as xT CDx with no changes to the current ordering workflow.

Biotech

General

Tempus Announces The Launch Of FDA-Approved xT CDx Test, Now Available For All Ordering Clinicians Nationwide

MYGN

Myriad Genetics Sees FY25 Adj. EPS $0.07-$0.11 Vs $0.08 Est.; Revenue $840M-$860M Vs $876.702M Est.

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>)&nbsp;a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as "Bird Flu." The Company is currently approaching potential university partners to expedite the preclinical work required for a Phase I study.
H5N1 is a viral infection often contracted by contact with sick birds, yet it can also be passed from person to person. Symptoms begin within two to eight days and can seem like the common flu, causing cough, fever, sore throat, muscle aches, headache, and shortness of breath. The disease can carry a high mortality in humans. Some antiviral drugs, if taken within two days of symptoms, may help. Last week, the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4340843-1&amp;h=149896997&amp;u=https%3A%2F%2Fldh.la.gov%2Fnews%2FH5N1-death&amp;a=Louisiana+Department+of+Health+recently+reported+the+first+U.S.+death+from+H5N1">Louisiana Department of Health recently reported the first U.S. death from H5N1</a>.

TCBP

TCBP Announces That It Intends To Begin Proof Of Concept Preclinical Studies For Its Lead Therapeutic TCB008, For Treatment In H5N1, Commonly Known As "Bird Flu"

Myriad Genetics Sees Prelim. Q4 Adj. EPS $0.03-$0.04 Vs $0.03 Est.; Revenue $209M-$211M Vs $212.873M Est.

JP Morgan analyst Tami Zakaria maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Neutral and raises the price target from $12 to $13.

JP Morgan Maintains Neutral on CNH Industrial, Raises Price Target to $13

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is gearing up to release its<a href="https://www.benzinga.com/quote/UNH/earnings"> fourth quarter earnings report</a>, and investors are watching closely. Stephanie Link, CIO at Hightower Advisors LLC, has dubbed the managed care giant the &#8220;number one company on sale&#8221; despite potential near-term earnings pressure.
<h2 class="wp-block-heading">&#8216;They&#8217;re Probably Gonna Miss&#8217; Q4 Earnings Expectations </h2>
With estimated earnings per share (EPS) of $6.73 and revenue projections around $101.75 billion according to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">Benzinga Pro</a> data, UnitedHealth faces scrutiny over high utilization rates that could dent its profit margins. 
On earnings, &#8220;they're probably gonna miss&#8230;because utilization rates are so strong, so high, and it hurts their cost,&#8221; Link <a href="https://www.cnbc.com/video/2025/01/14/trade-tracker-stephanie-link-buys-unitedhealth.html">remarked</a> during CNBC's Halftime Report. 
However, she sees this as a temporary hiccup, not a long-term trend.
Read Also: <a href="https://www.benzinga.com/general/health-care/24/12/42744629/unitedhealth-group-ceo-reportedly-says-company-will-hit-financial-records-execs-murder-public-outcry-are-backdrop-for-q4-earnings">UnitedHealth Group CEO Reportedly Says Company Will Hit Financial Records: Exec&#8217;s Murder, Public Outcry Are Backdrop For Q4 Earnings</a>
<h2 class="wp-block-heading">From Beat-And-Raise To Strategic Patience</h2>
UnitedHealth, long celebrated for its consistent earnings beats, hasn't seen much stock movement in the past year, but that hasn&#8217;t dampened Link&#8217;s enthusiasm. &#8220;They have a gem with Optum,&#8221; she said, referring to the segment responsible for 24% of the company's revenue and 12% of operating profits. 
Ongoing M&amp;A activity is bolstering Optum's growth trajectory, even as the broader healthcare sector struggles to find favor with investors.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM.png" alt="" class="wp-image-734548" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM-300x233.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Technically, UnitedHealth shares are experiencing bullish buying pressure, with the stock trading above its eight, 20 and 200-day simple moving averages (SMAs).
At $543.74 per share, the price positions UNH stock as a bullish signal across these metrics, although its moving average convergence/divergence (MACD) indicator of a negative 6.15 suggests caution. Meanwhile, UNH stock&#8217;s relative strength index (RSI) of 56.86 signals moderate strength but room for additional upward movement.
<h2 class="wp-block-heading">A Buying Opportunity In The Making?</h2>
Historically trading at a premium valuation, UnitedHealth now sits at 17 times earnings, compared to its typical 21 times multiple. &#8220;When I owned it, it was trading at something like 25 times, and every quarter was a beat and raise,&#8221; Link noted. Despite the temporary pressure, she believes the stock&#8217;s visibility will only improve post-earnings.
Link remains bullish on UnitedHealth&#8217;s potential, citing strong fundamentals, a promising $18 billion buyback program and expectations of double-digit earnings and revenue growth ahead. &#8220;We&#8217;re gonna see double-digit growth in earnings and revenues,&#8221; she emphasized, viewing current regulatory and litigation concerns as mere &#8220;noise.&#8221;
UnitedHealth's premium status as the &#8220;number one managed care company&#8221; may make today&#8217;s market lull a golden opportunity for savvy investors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/insights/news/25/01/42776487/heres-how-much-you-would-have-made-owning-unitedhealth-group-stock-in-the-last-10-years">Here&#8217;s How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years</a></li>
</ul>
Photo: Shutterstock

Health Care

Technicals

Previews

UnitedHealth: The 'Number One Company On Sale' Ahead Of Q4 Earnings Report

Benchmark analyst Christopher Kuhn reiterates RXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) from Hold to Hold.

Reiteration

Benchmark Reiterates Hold on RXOto Hold

Expansion into South Africa &amp; Nigeria Marks Ispire's First International Nicotine License Arrangement &amp; Product Launch
LOS ANGELES, Jan. 15, 2025 /PRNewswire/ -- <a href="https://ispiretechnology.com/">Ispire Technology Inc.</a>&nbsp;("Ispire" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>), an innovator in vaping technology and precision dosing, announced the successful launch of its BrkFst nicotine products across South Africa and Nigeria, marking the Company's first international nicotine license arrangement and product launch. BrkFst, the brand co-created by GRAMMY-Award winner Burna Boy, is set to redefine the nicotine product market in these regions.

Global

ISPR

Ispire Technology Announces License Arrangement And Successful Launch Of Burna Boy's BrkFst Nicotine Products Into African Markets

Offerings

AZTR

Azitra Prices 4,857,780 Share Public Offering Of Common Stock At $0.30/Share

Reports Q3 revenue R$841.19M vs. R$723.48M last year. The company said, "We are pleased to announce another quarter of solid results, marked by str...

Afya reports Q3 adjusted EPS R$1.79 vs. R$1.38 last year

Backs FY24 adjusted EBITDA view R$1.38B-R$1.48B. Backs FY24 capital expenditure view R$220M-R$260M. The company said, "Afya (AFYA) reaffirms the Gu...

Afya backs FY24 revenue view R$3.23B-R$3.33B

Afya Limited Class A ( ($AFYA) ) has released its Q3 earnings. Here is a breakdown of the information Afya Limited Class A presented to its investo...

Afya Limited Reports Strong Q3 2024 Financial Growth

Analyst Fred Mendes from Bank of America Securities maintained a Buy rating on Afya (AFYA – Research Report) and keeping the price target at $25.00...

Afya: Strong Financial Performance and Strategic Growth Justify Buy Rating

In a report released today, Mauricio Cepeda from Morgan Stanley maintained a Hold rating on Afya (AFYA – Research Report), with a price target of $...

Afya's Strong Growth Balanced by Acquisition Costs and Debt Concerns, Maintains Hold Rating

Afya Continues To Be An Opportunity Even After Brazil's Depreciation

Goldman Sachs initiated coverage of Afya (AFYA) with a Sell rating and $16 price target Afya is the largest medical education ecosystem in Brazil, ...

Afya initiated with a Sell at Goldman Sachs

07:18 EST Afya (AFYA) sinks 10% to $15.00 after Goldman starts with Sell rating Published first on TheFly – the ultimate source for real-time, mark...

Afya sinks 10% to $15.00 after Goldman starts with Sell rating

The latest update is out from Afya ( ($AFYA) ). Afya Limited announced the acquisition of Faculdade Única de Contagem through its subsidiary, addin...

Afya Limited Expands in Minas Gerais with Strategic Acquisition

Afya (AFYA) has entered into a share purchase agreement for the acquisition, through its wholly-owned subsidiary Afya Participacoes, of 100% of the...

Afya to acquire Faculdade Unica de Contagem for R$100M

Press Releases

Afya Limited Releases 2023 Sustainability Report

Afya Secures Loan of up to R$500 Million From IFC to Support the Company's Expansion

Afya Limited Announces Second-Quarter and First-Half 2024 Financial Results

Afya Secures Full Disbursement of R$500 Million From IFC to Support the Company's Expansion

Afya Limited Announces MEC Decision on Medical Seats Reconsideration in Unigranrio

Afya Assumes a Voluntary Commitment to Free Health Consultations

Afya Limited to Host Afya Day 2024 on October 29th | Hybrid Event

Afya Limited to Report Third Quarter and Nine Months 2024 Financial Results on November 13th

Afya Limited Third Quarter and Nine Months 2024 Financial Results

Afya Limited Announces Entering Into a Share Purchase Agreement for the Acquisition of Faculdade Única de Contagem

American Public Education, Inc. - Common Stock

American Public Education

Adtalem Glb Education

Bright Horizons Family Solutions Inc. Common Stock

Bright Horizons Family

Chegg

Coursera

Youdao, Inc. American Depositary Shares, each representing one Class A Ordinary Share

Youdao

Duolingo

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 10 Ordinary Share (Cayman Islands)

Comments

Afya

Afya (AFYA) Forecast

Afya (NASDAQ:AFYA) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga